Displaying 13 - 24 of 100
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Displaying 13 - 24 of 100